A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy and in Combination to Patients With Advanced or Metastatic Solid Tumors
This study is testing a new anti-cancer drug called ART0380, both by itself and combined with standard chemotherapy medications like gemcitabine or irinotecan. Researchers want to find the safest and most effective dose for treating advanced solid tumors that have spread.
You might be able to join if you have advanced solid tumors, such as ovarian, uterine, colorectal, or pancreatic cancer, that have spread. Participants must also meet specific health and lab requirements and have finished past treatments at least 21 days prior.
Participants will take the study drug by mouth, either alone or with chemotherapy, while closely monitored by the medical team. Doctors will check your health, track side effects, and use scans to see how well the treatment is working.
This study is currently recruiting patients at multiple locations, including sites in Alabama, Arizona, and Arkansas. You can talk to your care team to see if one of these locations is right for you.
- 1Testing a new cancer drug called ART0380 alone and with chemotherapy
- 2Open to patients with certain advanced or metastatic solid tumors
- 3Currently recruiting participants at select locations in the United States
No related links yet
Seen this study covered in the news, or found a page that explains it well? Send it over and we'll review it.
Suggest a linkThis summary was generated using AI and may not capture all details. Always consult with a healthcare professional for medical advice.